{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976452",
  "id": "02976452",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250804",
  "time": "0934",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhk1f91vq65q.pdf",
  "summary": "- **Capital Raising Announcement**:  \n  - **Structure**: Placement with attaching options  \n  - **Total Capital Raised**: AUD ~2.82M (188,333,333 shares @ AUD 0.015)  \n  - **Key Dates**:  \n    - Shareholder approval meeting: 18/9/2025  \n    - Proposed issue date: 22/9/2025  \n  - **Attaching Securities**:  \n    - 233,333,333 options (IBXO, expiring 13-Dec-2027, free with shares)  \n    - 26,250,000 unlisted options (exercise price AUD 0.04, expiring 17-Sep-2028) for lead manager  \n  - **Use of Proceeds**: Fund MagSense\u00ae HER2 Breast Cancer tech and Phase 1 trials for prostate/ovarian cancer.  \n  - **Lead Manager**: CPS Capital (4% fee + 2.625M options).  \n\n*Omitted non-material details (e.g., administrative conditions, escrow terms).*",
  "usage": {
    "prompt_tokens": 2586,
    "completion_tokens": 222,
    "total_tokens": 2808,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-03T23:54:43.364919"
}